Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Singapore's EDB, GSK In Green Manufacturing Research Tie Up

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - GlaxoSmithKline and Singapore's Economic Development Board have committed $35 million toward research into green manufacturing

You may also be interested in...



As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups

SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions

As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups

SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions

GSK Says "Unique" Collaboration With Singapore Academics Aimed Squarely At Drug Discovery

SINGAPORE - GlaxoSmithKline said four new drug research collaborations between Singapore-based academics and GSK's global drug discovery network are "unique" alliances for the firm, pairing seasoned researchers from GSK's global network with promising academic work to bring new drugs to the market

Latest News
See All
UsernamePublicRestriction

Register

SC075583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel